Development of vaccines to improve porcine health

Vaccine development for an emerging, diarrhea-causing coronavirus in pigs

Coronaviruses are important pathogens of both human and veterinary relevance. Enteric coronaviruses of farm and companion animals often cause significant morbidity/mortality, with consequential economic losses in the case of livestock animals. A prominent enteric coronavirus is the emerging porcine epidemic diarrhea virus (PEDV), which can cause severe diarrhea with a fatality rate approaching 100% in young piglets. To protect animals against the clinical outcome of these serious infections, pigs can be vaccinated with live-attenuated virus (LAV) vaccines.

The aim of this project is to develop such a vaccine against PEDV based on a recombinant live-attenuated virus (rLAV). This vaccine will be developed using the PEDV reverse-genetics system recently developed by UU. Development of this PEDV vaccine is not only of veterinary significance but will also give important insights in reverse-genetics vaccine strategies against coronaviruses in general. This is important because coronaviruses are well-known for their zoonotic potential, as MERS and SARS.  

Thus, the research proposed in the project will provide a basis for vaccine strategies against future emerging zoonotic coronavirus infections in humans as well and thereby preventing the burden of healthcare in infectious disease outbreaks.  

Summary
The aim of this project is to develop a vaccine against the emerging porcine epidemic diarrhea virus - which can cause severe diarrhea with a fatality rate approaching 100% in young piglets - based on a recombinant live-attenuated virus approach.
Technology Readiness Level (TRL)
NULL
Time period
48 months
Partners